Brief: Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma
15/05/2024 13:39
May 15 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN ANNOUNCES COMMENCEMENT OF NIH-FUNDED PHASE 2
CLINICAL
TRIAL OF STAT3 INHIBITOR FOR THE TREATMENT OF GLIOBLASTOMA (NU
21C06)
Source text for Eikon: ID:nPn3GmJvTa
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM